Search research articles
Contact Us
Filters
Showing results (21-30 of 41) with videos related to
Page
of 5
Sort By:
Journal of Clinical Pharmacology
|
December 4, 2015
Phase 1 Study of ABT-751 in Combination With CAPIRI (Capecitabine and Irinotecan) and Bevacizumab in Patients With Advanced Colorectal Cancer
Michelle A Rudek, Arvind Dasari, Daniel Laheru, et al.
Investigational New Drugs
|
March 23, 2010
Thymidylate synthase (TYMS) enhancer region genotype-directed phase II trial of oral capecitabine for 2nd line treatment of advanced pancreatic cancer
Colin D Weekes, Sujatha Nallapareddy, Michelle A Rudek, et al.
Translational Oncology
|
December 15, 2010
A tolerability and pharmacokinetic study of adjuvant erlotinib and capecitabine with concurrent radiation in resected pancreatic cancer
Wen Wee Ma, Joseph M Herman, Antonio Jimeno, et al.
International Journal of Radiation Oncology, Biology, Physics
|
February 6, 2007
Adjuvant concurrent chemoradiation for adenocarcinoma of the distal common bile duct
Michael A Hughes, Deborah A Frassica, Charles J Yeo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 1, 2009
A phase I dose-finding study of 5-azacytidine in combination with sodium phenylbutyrate in patients with refractory solid tumors
Jianqing Lin, Jill Gilbert, Michelle A Rudek, et al.
Clinical Colorectal Cancer
|
January 7, 2011
Phase I trial of oxaliplatin, infusional 5-fluorouracil, and leucovorin (FOLFOX4) with erlotinib and bevacizumab in colorectal cancer
Wells A Messersmith, Antonio Jimeno, Heather Jacene, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 12, 2002
Impact of prolonged infusions of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia
Steven D Gore, Li-Jun Weng, William D Figg, et al.
Cancer Chemotherapy and Pharmacology
|
July 30, 2011
A multicenter analysis of GTX chemotherapy in patients with locally advanced and metastatic pancreatic adenocarcinoma
Ana De Jesus-Acosta, George R Oliver, Amanda Blackford, et al.
The Lancet. Oncology
|
June 27, 2014
Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study
Timothy Iveson, Ross C Donehower, Irina Davidenko, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 25, 2003
Phase I study of docosahexaenoic acid-paclitaxel: a taxane-fatty acid conjugate with a unique pharmacology and toxicity profile
Antonio C Wolff, Ross C Donehower, M Katherine Carducci, et al.
Page
of 5
Search research articles
Search
Showing results (21-30 of 41) with videos related to
Sort By:
Page
of 5
Journal of Clinical Pharmacology
|
December 4, 2015
Phase 1 Study of ABT-751 in Combination With CAPIRI (Capecitabine and Irinotecan) and Bevacizumab in Patients With Advanced Colorectal Cancer
Michelle A Rudek, Arvind Dasari, Daniel Laheru, et al.
Investigational New Drugs
|
March 23, 2010
Thymidylate synthase (TYMS) enhancer region genotype-directed phase II trial of oral capecitabine for 2nd line treatment of advanced pancreatic cancer
Colin D Weekes, Sujatha Nallapareddy, Michelle A Rudek, et al.
Translational Oncology
|
December 15, 2010
A tolerability and pharmacokinetic study of adjuvant erlotinib and capecitabine with concurrent radiation in resected pancreatic cancer
Wen Wee Ma, Joseph M Herman, Antonio Jimeno, et al.
International Journal of Radiation Oncology, Biology, Physics
|
February 6, 2007
Adjuvant concurrent chemoradiation for adenocarcinoma of the distal common bile duct
Michael A Hughes, Deborah A Frassica, Charles J Yeo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 1, 2009
A phase I dose-finding study of 5-azacytidine in combination with sodium phenylbutyrate in patients with refractory solid tumors
Jianqing Lin, Jill Gilbert, Michelle A Rudek, et al.
Clinical Colorectal Cancer
|
January 7, 2011
Phase I trial of oxaliplatin, infusional 5-fluorouracil, and leucovorin (FOLFOX4) with erlotinib and bevacizumab in colorectal cancer
Wells A Messersmith, Antonio Jimeno, Heather Jacene, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 12, 2002
Impact of prolonged infusions of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia
Steven D Gore, Li-Jun Weng, William D Figg, et al.
Cancer Chemotherapy and Pharmacology
|
July 30, 2011
A multicenter analysis of GTX chemotherapy in patients with locally advanced and metastatic pancreatic adenocarcinoma
Ana De Jesus-Acosta, George R Oliver, Amanda Blackford, et al.
The Lancet. Oncology
|
June 27, 2014
Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study
Timothy Iveson, Ross C Donehower, Irina Davidenko, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 25, 2003
Phase I study of docosahexaenoic acid-paclitaxel: a taxane-fatty acid conjugate with a unique pharmacology and toxicity profile
Antonio C Wolff, Ross C Donehower, M Katherine Carducci, et al.
Page
of 5